Related Experiment Video
Updated: Mar 7, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
[Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion]
C Kuhli-Hattenbach1, P Hellstern2, W Miesbach3
1Klinik für Augenheilkunde, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Deutschland. hattenbach@med.uni-frankfurt.de.
Background:
The potential impact of multiple thrombophilic defects on retinal venous occlusive (RVO) diseases with regard to age and various risk factors has not been studied extensively.
Materials And Methods:
In a retrospective, multicenter study, thrombophilia data of 128 patients <65 years of age with RVO and 110 healthy subjects were evaluated. The main measure outcome was the prevalence of multiple thrombophilic disorders.
Results:
Multiple thrombophilic defects were significantly more prevalent among RVO patients (18.0%) than among controls (1.8%; P < 0.0001). We identified factor VIII elevation, elevated lipoprotein(a) plasma levels and resistance to activated protein C as the most prevalent combined disorders. Factor XII deficiency and prothrombin mutation G20210A were found to be isolated thrombophilic risk factors. Multiple thrombophilic defects were significantly associated with RVO recurrence (P = 0.008).
Conclusion:
Multiple thrombophilic disorders are associated with the development of RVO among patients younger than 65 years of age. Moreover, our results suggest that patients with RVO associated with underlying combined thrombophilic defects are at increased risk for RVO recurrence. Further studies are required to analyze whether the diagnosis of combined thrombophilic defects among RVO patients could be a predictor for RVO recurrence.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

